Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Use of Quaking-Induced Conversion (QUIC) for Detection of Prions Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before November 4, 2013 will be considered.
View Prospective Grant of Exclusive Commercialization License: The Use of Cysteamine for the Treatment of Pancreatic Cancer, Breast Cancer and Hepatocellular Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 28, 2013 will be considered.
View Draft NIH Genomic Data Sharing Policy Request for Public Comments To ensure that your comments will be considered, please submit your response to this Request for Comments no later than 60 days after publication of this notice.
View Prospective Grant of Exclusive Patent License: Oral Treatment of Hemophilia Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before October 21, 2013 will be considered.
View Prospective Grant of Exclusive Patent License: Use of Exenatide for the Treatment of Neurodegenerative Diseases Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 27, 2013 will be considered.
View Prospective Grant of Exclusive Patent License: Use of Scopolamine to Treat Depression Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 26, 2013 will be considered.
View Prospective Grant of Exclusive License: Development of Brachyury Tumor Associated Antigens as Cancer Vaccines for Colorectal Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 18, 2013 will be considered.
View Prospective Grant of Start-up Exclusive License: Kits for the Detection of Human Interferon-Alpha Subtypes and Allotypes Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before August 16, 2013 will be considered.
View Prospective Grant of Start-up Exclusive License: Topical Antibiotic With Immune Stimulating Oligodeoxynucleotide Molecules To Speed Wound Healing; and Use of CpG Oligodeoxynucleotides To Induce Epithelial Cell Growth Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before August 16, 2013 will be considered.
View Prospective Grant of Exclusive License: Live Attenuated Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4 Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 19, 2013 will be considered.
View Prospective Grant of Exclusive License: Ophthalmic Diagnostic Devices Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before July 31, 2013 will be considered.
View Prospective Grant of an Exclusive License: Human Papillomavirus 16 E2 and E6 Peptides for Cervical Cancer Vaccine Development Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before August 15, 2013 will be considered.
View Prospective Grant of Start-Up Exclusive Evaluation Option License: Methods of Treating Giardiasis Using Available Compounds Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before July 31, 2013 will be considered.
View Prospective Grant of Start-Up Exclusive Commercialization License: The Development of a Circularly Permuted IL4-Targeted Pseudomonas Exotoxin A (cpIL4-PE38KDEL) for the Treatment of Cancers and Urological Disorders Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 23, 2013 will be considered.
View Prospective Grant of Exclusive License: Start-Up Commercial License for the Development of Fenoterol and Fenoterol Analogues for the Treatment of Brain, Liver, and Pancreatic Cancers and Congestive Heart Failure Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before July 5, 2013 will be considered.
View Prospective Grant of Exclusive License: Modulation of Poliovirus Replicative Fitness by Deoptimization of Synonymous Codons Only written comments and/or applications for a license which are received by CDC on or before July 15, 2013 will be considered.
View Prospective Grant of Start-up Exclusive Evaluation License: Portable Device and Method for Detecting Hematomas Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before June 25, 2013 will be considered.
View Prospective Grant of Co-Exclusive Licenses: Multi-Focal Structured Illumination Microscopy Systems and Methods Only written comments and/or applications for a license that are received by the NIH Office of Technology Transfer on or before August 2, 2013 will be considered.
View Prospective Grant of a Start-Up Exclusive Patent License Agreement: Treatment of Graves' Disease, Hyperthyroidism and Thyroid Cancer Only written comments or applications for a license (or both) which are received by the NIH Office of Technology Transfer on or before June 10, 2013 will be considered.
View Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: In Vitro Diagnostics for Prediction of Therapeutic Efficacy in Cancer and Other Angiogenesis-Mediated Diseases Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 31, 2013 will be considered.
View Prospective Grant of Exclusive License: Device and System for Expression Microdissection (xMD) Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 29, 2013 will be considered.
View Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: Gene Therapy and Cell-Based Therapy for Cardiac Arrhythmias Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 23, 2013 will be considered.
View Prospective Grant of Exclusive License: Use of Oligodeoxynucleotide as Neuroprotectants in Cerebral and Other Ischemic Injury Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before June 7, 2013 will be considered.
View Prospective Grant of Start-Up Exclusive License: 1. Catalytic Domains of Beta (1,4)-Galactosyltransferase I Having Altered Donor and Acceptor Specificities Domains, That Promote in Vitro Protein Folding and Methods for Their Use; 2. Targeted Delivery System for Bioactive Agents Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before May 22, 2013 will be considered.
View National Institutes of Health Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 13, 2013 will be considered.